ID
    JP2019022506A
citation_exist
    Patent Citations (26)
citation_infor
28
    Publication number,Priority date,Publication date,Assignee,Title
    Family To Family Citations,,,,
    NL154600B,1971-02-10,1977-09-15,Organon Nv,Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
    NL154598B,1970-11-10,1977-09-15,Organon Nv,Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
    NL154599B,1970-12-28,1977-09-15,Organon Nv,Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
    US3901654A,1971-06-21,1975-08-26,Biological Developments,Receptor assays of biologically active compounds employing biologically specific receptors
    US3853987A,1971-09-01,1974-12-10,W Dreyer,Immunological reagent and radioimmuno assay
    US3867517A,1971-12-21,1975-02-18,Abbott Lab,Direct radioimmunoassay for antigens and their antibodies
    NL171930C,1972-05-11,1983-06-01,Akzo Nv,Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
    US3850578A,1973-03-12,1974-11-26,H Mcconnell,Process for assaying for biologically active molecules
    US3935074A,1973-12-17,1976-01-27,Syva Company,Antibody steric hindrance immunoassay with two antibodies
    US3996345A,1974-08-12,1976-12-07,Syva Company,Fluorescence quenching with immunological pairs in immunoassays
    US4034074A,1974-09-19,1977-07-05,The Board Of Trustees Of Leland Stanford Junior University,Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
    US3984533A,1975-11-13,1976-10-05,General Electric Company,Electrophoretic method of detecting antigen-antibody reaction
    US4098876A,1976-10-26,1978-07-04,Corning Glass Works,Reverse sandwich immunoassay
    US4879219A,1980-09-19,1989-11-07,General Hospital Corporation,Immunoassay utilizing monoclonal high affinity IgM antibodies
    US5011771A,1984-04-12,1991-04-30,The General Hospital Corporation,Multiepitopic immunometric assay
    US4666828A,1984-08-15,1987-05-19,The General Hospital Corporation,Test for Huntington's disease
    US4683202B1,1985-03-28,1990-11-27,Cetus Corp,
    US4801531A,1985-04-17,1989-01-31,Biotechnology Research Partners, Ltd.,Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
    US5272057A,1988-10-14,1993-12-21,Georgetown University,Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
    US5192659A,1989-08-25,1993-03-09,Genetype Ag,Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
    US5281521A,1992-07-20,1994-01-25,The Trustees Of The University Of Pennsylvania,Modified avidin-biotin technique
    US5792638A                      *,1994-05-24,1998-08-11,The United States Of America As Represented By The Department Of Health And Human Services,Human ras-related oncogenes unmasked by expression cDNA cloning
    CA2282658C,1997-02-27,2003-02-25,Cellomics, Inc.,A system for cell-based screening
    US20040115659A1                      *,2001-08-29,2004-06-17,Benjamin Geiger,Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
    US6808906B2,2002-05-08,2004-10-26,Rigel Pharmaceuticals, Inc.,Directionally cloned random cDNA expression vector libraries, compositions and methods of use
    US20100196898A1                      *,2007-05-24,2010-08-05,The Brigham & Women's Hospital, Inc.,Disease-associated genetic variations and methods for obtaining and using same

non_patent_citation_exist
    NoNonPatentCitation
non_patent_citation_infor
    NoNonPatentCitation
citedBy_exist
    
              Cited By (5)
              


citedBy_infor
7
    Publication number,Priority date,Publication date,Assignee,Title
    Family To Family Citations,,,,
    CA2955411A1,2014-07-21,2016-01-28,Novellusdx Ltd.,Methods for determining drug response of patient specific mutations
    EP3172562B1                      *,2014-07-21,2019-03-13,Novellusdx Ltd.,Methods and systems for determining oncogenic index of patient specific mutations
    CN109134662B                      *,2017-06-27,2021-07-20,中国农业科学院北京畜牧兽医研究所,一种可视化抗菌肽融合蛋白及其制备方法和其应用
    CN107151707B                      *,2017-06-27,2020-11-17,迈基诺（重庆）基因科技有限责任公司,一种检测肺癌相关基因热点突变的试剂盒及其应用
    US11773449B2,2017-09-01,2023-10-03,The Hospital For Sick Children,Profiling and treatment of hypermutant cancer

abstract
    【課題】患者特有のドライバー変異を特定するための方法を提供する。【解決手段】癌患者の異常なシグナル伝達経路を引き起こす変異を同定する方法であって、ａ）患者の試料または患者の腫瘍分子プロファイリングデータを取得することと、ｂ）前記患者に存在する試験遺伝子変異を含む発現ベクターを作製することと、ｃ）前記試験遺伝子に対応する野生型遺伝子を含む対照の発現コンストラクトを作製することと、ｄ）蛍光トランスロケーションレポーター（ＦＴＲ）をコードする発現ベクターを作製することと、ｅ）前記発現ベクタ—をアッセイ細胞へトランスフェクトすることと、ｆ）前記変異試験遺伝子または野生型遺伝子と前記ＦＴＲの発現を可能にするのに十分な時間で前記アッセイ細胞をインキュベートすることと、ｇ）前記細胞内の前記ＦＴＲの細胞内局在を決定することと、を含む方法。【選択図】なし
title
    患者特有のドライバー変異を特定するための方法およびシステム
similar_document
16
    Publication,Publication Date,Title
    US20210199660A1,2021-07-01,Biomarkers of breast cancer
    JP6873089B2,2021-05-19,患者特有のドライバー変異を特定するための方法およびシステム
    Majewski et al.,2013,Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
    JP6223451B2,2017-11-01,がんの診断及び治療方法
    US20170114415A1,2017-04-27,Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
    CN101454668A,2009-06-10,癌症预测与预后以及监测癌症治疗的方法
    JP2014509868A,2014-04-24,癌の予後のための遺伝子発現予測因子
    Kawakami et al.,2013,Detection of novel paraja ring finger 2‐fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non‐small cell lung cancer
    Seidl et al.,2002,Three‐dimensional fibroblast–tumor cell interaction causes downregulation of RACK1 mRNA expression in breast cancer cells in vitro
    JP6837428B2,2021-03-10,患者特有の変異の発癌性指数を決定する方法およびシステム
    JP6700249B2,2020-06-10,患者特有の変異の薬物応答を測定する方法
    IL239624A,2017-01-31,Methods and systems for identifying specific patient mutations
    US10480032B2,2019-11-19,Use of EI24 gene
    JP2006166789A,2006-06-29,癌の新規診断方法
    WO2010128029A2,2010-11-11,Biomarkers for predicting responsiveness of rectal cancers to radiochemotherapy

patent_application
2
    Application,Priority date,Filing date,Relation,Title
    JP2015553227A,2013-01-17,2014-01-16,Division,患者特有のドライバー変異を特定するための方法およびシステム

patent_priority_application
    NoExist
inventor_number
    6
classfication_nums
    12
classfication_items
77
    C
    C,1,2
    C,1,2,N
    C,1,2,N,1,5,/,0,0
    C,1,2,N,1,5,/,0,9
    C,1,2,N,1,5,/,1,0
    C,1,2,N,1,5,/,1,0,3,4
    C,1,2,N,1,5,/,1,0,5,5
    H
    H,0,2
    H,0,2,J
    H,0,2,J,7,/,0,0
    H,0,2,J,7,/,1,4
    H,0,2,J,7,/,1,6
    B
    B,6,0
    B,6,0,L
    B,6,0,L,7,/,0,0
    B,6,0,L,7,/,1,0
    B,6,0,L,7,/,1,2
    C
    C,1,2
    C,1,2,Q
    C,1,2,Q,1,/,0,0
    C,1,2,Q,1,/,6,8
    C,1,2,Q,1,/,6,8,7,6
    C,1,2,Q,1,/,6,8,8,3
    C,1,2,Q,1,/,6,8,8,6
    G
    G,0,1
    G,0,1,N
    G,0,1,N,2,1,/,0,0
    G,0,1,N,2,1,/,6,2
    G,0,1,N,2,1,/,6,3
    G,0,1,N,2,1,/,6,4
    G,0,1,N,2,1,/,6,4,2,8
    H
    H,0,2
    H,0,2,J
    H,0,2,J,7,/,0,0
    H,0,2,J,7,/,3,2
    B
    B,6,0
    B,6,0,L
    B,6,0,L,2,2,0,0,/,0,0
    B,6,0,L,2,2,0,0,/,2,2
    B
    B,6,0
    B,6,0,L
    B,6,0,L,2,2,2,0,/,0,0
    B,6,0,L,2,2,2,0,/,4,0
    B,6,0,L,2,2,2,0,/,4,2
    B
    B,6,0
    B,6,0,L
    B,6,0,L,2,2,4,0,/,0,0
    B,6,0,L,2,2,4,0,/,4,0
    B,6,0,L,2,2,4,0,/,5,2
    B,6,0,L,2,2,4,0,/,5,2,7
    B
    B,6,0
    B,6,0,L
    B,6,0,L,2,2,4,0,/,0,0
    B,6,0,L,2,2,4,0,/,4,0
    B,6,0,L,2,2,4,0,/,5,2
    B,6,0,L,2,2,4,0,/,5,2,9
    B
    B,6,0
    B,6,0,L
    B,6,0,L,2,2,6,0,/,0,0
    B,6,0,L,2,2,6,0,/,2,0
    B,6,0,L,2,2,6,0,/,2,8
    C
    C,1,2
    C,1,2,Q
    C,1,2,Q,2,6,0,0,/,0,0
    C,1,2,Q,2,6,0,0,/,1,5,8

application_events
6
    2018-09-26,Application filed by NOVELLUSDX Ltd
    2019-02-14,Publication of JP2019022506A
    2021-05-19,Application granted
    2021-05-19,Publication of JP6873089B2
    Status,Active
    2034-01-16,Anticipated expiration

active_area
10
    C,N
    W,O
    U,S
    J,P
    C,A
    E,S
    E,P
    I,L
    U,S
    J,P

not_active_area
1
    E,P

patent_application_claiming_priority
3
    Application,Filing date,Title
    US201361753458P,2013-01-17,
    US61/753,458,2013-01-17,

legal_event
14
    Date,Code,Title,Description
    2018-09-26,A621,Written request for application examination,Free format text: JAPANESE INTERMEDIATE CODE: A621Effective date: 20180926
    2019-08-13,A131,Notification of reasons for refusal,Free format text: JAPANESE INTERMEDIATE CODE: A131Effective date: 20190813
    2019-11-08,A601,Written request for extension of time,Free format text: JAPANESE INTERMEDIATE CODE: A601Effective date: 20191108
    2020-01-10,A521,Request for written amendment filed,Free format text: JAPANESE INTERMEDIATE CODE: A523Effective date: 20200110
    2020-06-23,A131,Notification of reasons for refusal,Free format text: JAPANESE INTERMEDIATE CODE: A131Effective date: 20200623
    2020-09-15,A601,Written request for extension of time,Free format text: JAPANESE INTERMEDIATE CODE: A601Effective date: 20200915
    2020-11-20,A521,Request for written amendment filed,Free format text: JAPANESE INTERMEDIATE CODE: A523Effective date: 20201120
    2021-03-23,TRDD,Decision of grant or rejection written,
    2021-03-30,A01,Written decision to grant a patent or to grant a registration (utility model),Free format text: JAPANESE INTERMEDIATE CODE: A01Effective date: 20210330
    2021-04-22,A61,First payment of annual fees (during grant procedure),Free format text: JAPANESE INTERMEDIATE CODE: A61Effective date: 20210420
    2021-04-22,R150,Certificate of patent or registration of utility model,Ref document number: 6873089Country of ref document: JPFree format text: JAPANESE INTERMEDIATE CODE: R150
    2022-07-12,S533,Written request for registration of change of name,Free format text: JAPANESE INTERMEDIATE CODE: R313533
    2022-07-21,R350,Written notification of registration of transfer,Free format text: JAPANESE INTERMEDIATE CODE: R350

